We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
mRNA Vaccine-Based Anti-monkeypox Drug Discovery Solutions
The monkeypox virus causes an emerging high-threat zoonotic disease, which is the most serious human poxvirus infection since smallpox was eradicated. The transmission and infection of monkeypox worldwide have led to a series of human health problems and even death, which became a disease of public health importance. The prevention of monkeypox transmission and the treatment of monkeypox virus-caused disease have become the most urgent problems to be addressed. Due to their high potency, rapid development potential, cost-effective manufacturing, and safe administration, messenger RNA (mRNA) vaccines represent a promising alternative to traditional vaccine approaches and are growing extremely rapidly in the vaccine field. Creative Biolabs has been committed to the vaccine development field for over a decade. We provide professional support for mRNA vaccine-based anti-monkeypox drug discovery program design and provide mRNA vaccine-related products.
Advantages of the mRNA Vaccine Against Monkeypox
mRNA vaccines are non-infectious, as they are not constructed from active or inactive viruses.
mRNA vaccines are non-integrating. The extranuclear translation of mRNA occurs in the cytoplasm, therefore having a low risk of mutagenesis.
mRNA vaccines have high efficacy rates, as they stimulate both cellular immunity and humoral immunity due to their intracellular production of antigens.
Cost-effective, rapid, and standard manufacturing.
Rapid development and simple modification to make mRNA vaccines more stable and translatable.
mRNA modifications used in vaccines against monkeypox may include nucleoside modifications and sequence engineering. Incorporating modified nucleosides such as pseudouridines and 2'-O-methylated nucleosides into the mRNAs could inhibit the stimulation of the immune response and enhance stabilization and translational capacity. Sequence engineering of the open reading frame (ORF) and untranslated regions (UTR) of mRNA could increase antigen translation for immune response, which reduces the initiating material and hence decreases the costs.
However, due to their low thermostability, mRNA vaccines need to be kept at low temperatures to avoid degradation. As the mRNA vaccine is an emerging technology, there remain many unknown effects or side effects, especially on people who are susceptible to autoimmune disorders. To address these shortcomings, Creative Biolabs provides a reliable mRNA vaccine drug development platform for customers worldwide to explore low-toxic, hyposensitive, stable, and highly effective anti-monkeypox drugs.
Vaccine-based Anti-Monkeypox Drug Discovery Solutions at Creative Biolabs
Creative Biolabs is very proud to provide comprehensive mRNA vaccine-based anti-monkeypox drug discovery solutions to discover effective mRNA vaccines against monkeypox with low toxicity, few side effects, and high stability. We provide anti-monkeypox products and services, including but not limited to high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services. Our dedicated team helps you design customized mRNA vaccines against the monkeypox virus for your specific application and assists you in solving your expertise questions. For more detailed information about mRNA vaccine-based anti-monkeypox drug discovery solutions, please don't hesitate to contact us.